Douglas Lane & Associates LLC Decreases Stake in Elanco Animal Health Incorporated $ELAN

Douglas Lane & Associates LLC lessened its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 12.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,275,577 shares of the company's stock after selling 323,497 shares during the quarter. Douglas Lane & Associates LLC owned about 0.46% of Elanco Animal Health worth $50,950,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in ELAN. GAMMA Investing LLC grew its stake in Elanco Animal Health by 14.1% during the third quarter. GAMMA Investing LLC now owns 14,199 shares of the company's stock valued at $318,000 after acquiring an additional 1,750 shares in the last quarter. Farther Finance Advisors LLC boosted its stake in Elanco Animal Health by 12.5% during the third quarter. Farther Finance Advisors LLC now owns 4,184 shares of the company's stock valued at $94,000 after buying an additional 464 shares during the last quarter. Artemis Investment Management LLP increased its stake in Elanco Animal Health by 55.5% in the 3rd quarter. Artemis Investment Management LLP now owns 4,611,977 shares of the company's stock worth $103,262,000 after acquiring an additional 1,645,331 shares during the last quarter. Versant Capital Management Inc boosted its position in shares of Elanco Animal Health by 26.3% during the 3rd quarter. Versant Capital Management Inc now owns 11,435 shares of the company's stock valued at $256,000 after acquiring an additional 2,380 shares during the last quarter. Finally, State Street Corp increased its position in Elanco Animal Health by 4.7% in the second quarter. State Street Corp now owns 16,063,046 shares of the company's stock worth $395,312,000 after purchasing an additional 726,567 shares during the last quarter. 97.48% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, Director Lawrence Kurzius acquired 40,000 shares of the firm's stock in a transaction that occurred on Thursday, August 20th. The stock was bought at an average price of $23.40 per share, for a total transaction of $936,000.00. Following the acquisition, the director directly owned 188,647 shares of the company's stock, valued at $4,414,339.80. This represents a 26.91% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Michael Harrington acquired 5,000 shares of the firm's stock in a transaction that occurred on Wednesday, August 12th. The shares were bought at an average price of $21.82 per share, with a total value of $109,100.00. Following the acquisition, the director directly owned 131,451 shares in the company, valued at $2,868,260.82. This represents a 3.95% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought a total of 63,198 shares of company stock worth $1,473,109 over the last ninety days. 1.14% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities analysts have commented on ELAN shares. KeyCorp reissued an "overweight" rating on shares of Elanco Animal Health in a research note on Wednesday, September 30th. Weiss Ratings raised shares of Elanco Animal Health from a "sell (d)" rating to a "sell (d+)" rating in a report on Friday, September 4th. Morgan Stanley boosted their price objective on Elanco Animal Health from $23.00 to $26.00 and gave the stock an "equal weight" rating in a research note on Wednesday, July 22nd. Piper Sandler restated an "overweight" rating on shares of Elanco Animal Health in a research report on Monday, June 29th. Finally, UBS Group raised their price objective on Elanco Animal Health from $31.00 to $33.00 and gave the company a "buy" rating in a research note on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $29.70.

Elanco Animal Health Trading Up 1.3%

Shares of ELAN traded up $0.30 during mid-day trading on Friday, reaching $22.84. 678,423 shares of the company's stock traded hands, compared to its average volume of 5,633,295. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.05 and a quick ratio of 1.10. The stock's 50-day moving average is $23.47 and its two-hundred day moving average is $23.64. Elanco Animal Health Incorporated has a 12 month low of $19.40 and a 12 month high of $27.98. The stock has a market cap of $11.41 billion, a P/E ratio of -55.74, a P/E/G ratio of 1.59 and a beta of 1.70.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.27 by $0.07. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%.The company had revenue of $1.37 billion during the quarter, compared to analysts' expectations of $1.31 billion. During the same quarter in the previous year, the business earned $0.26 EPS. Elanco Animal Health's revenue was up 10.2% compared to the same quarter last year. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. Research analysts forecast that Elanco Animal Health Incorporated will post 1.13 earnings per share for the current fiscal year.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated is a global animal health company that develops, manufactures and markets products for pets and food-producing animals. Its portfolio includes veterinary pharmaceuticals, vaccines, parasiticides, nutritional products and other solutions designed to prevent and treat disease, improve animal well-being and support livestock productivity.

For companion animals, Elanco offers products addressing pain, osteoarthritis, dermatological conditions, infectious diseases and flea, tick and intestinal parasite control.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.